Novartis Ag Stock News

The OTC Anti-Infective Drug Market research report is one point solution for businesses to evolve, grow, and mature. It provides real-time data collection methods that can track niche products growth that aligns with your goals. The insights and statistical models

The Recombinant Vector Vaccines market research report provides an in-depth analysis of the currents trends, latest developments, scenarios, market sizes, various drivers, restraints, and major players along with their profile details. The research report offers the historic data for years

Professional Advisory Services Inc. increased its position in shares of Novartis AG (NYSE:NVS) by 7.7% in the third quarter, HoldingsChannel.com reports. The firm owned 267,779 shares of the companys stock after acquiring an additional 19,077 shares during the quarter. Novartis comprises 3.2% of Professional Advisory Services Inc.s holdings, making the stock its 16th largest position. []

Novartis AG (NYSE:NVS) Analysts at Jefferies Financial Group boosted their FY2021 earnings estimates for shares of Novartis in a research report issued on Wednesday, November 10th. Jefferies Financial Group analyst P. Welford now anticipates that the company will post earnings per share of $6.38 for the year, up from their prior estimate of $6.30. []

IGRO: International Dividend Growth

Since being spun off into a separate company in April 2019, Alcon Inc. ( ALC , Financial) shares have thrived while the stock of its former parent, Novartis AG ( NVS , Financial), has languished.

Novartis AG (NYSE: NVS) terminated its ex-US rights to the program dubbed vibecotamab, a bispecific targeting CD123 and CD3 for acute myeloid leukemia.  The move will take effect next February, X

The market is up 8% in a few weeks, and the 28% overvalued S&P 500 offers near-zero inflation and risk-adjusted expected returns over the next five years. Fortunately, there are always wonderful blue-

Roche's $20.7 billion move to buy back nearly a third of its voting stock from fellow Swiss drugmaker Novartis will give it more strategic flexibility, Chairman Christoph Franz said in an interview pu

Novartis AG (NYSE: NVS) has announced Phase 2 trial data of iptacopan, a selective factor B inhibitor, in patients with C3 glomerulopathy (C3G). In C3G, an overly-active alternative complement pathwa

A Roche shareholder since 2001, Novartis expects to report a gain of $14 billion from the stake sale, which disentangles two pharma rivals.

Novartis AG and Roche Holding AG said Thursday that the Swiss pharmaceutical companies have agreed for Novartis to sell its holding of Roche bearer shares to Roche for a total consideration of $20.7 b

Novartis AG, a shareholder in Roche for more than 20 years, said on Thursday the two Swiss drugmakers had agreed that Roche would buy Novartis's nearly one-third voting stake in its cross-town rival f

The U.K.-based Dunad Therapeutics has entered a strategic collaboration and license agreement with Novartis AG (NYSE: NVS) to generate orally bioavailable covalent and protein degrading small mo

The FDA has approved Novartis AG's (NYSE: NVS) Scemblix (asciminib) for chronic myeloid leukemia (CML) in two distinct indications.  The FDA granted Scemblix accelerated approval for adult patient